-
Mashup Score: 2Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer - 9 month(s) ago
PURPOSE Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity in endometrial cancer (EC). The primary end point was to assess progression-free survival (PFS) with once-weekly oral selinexor in patients with advanced or recurrent EC. PATIENTS AND METHODS ENGOT-EN5/GOG-3055/SIENDO was a randomized, prospective, multicenter, double-blind, placebo-controlled, phase III study at 107 sites in 10 countries. Patients 18 years or older with histologically confirmed EC were enrolled. All had completed a single line of at least 12 weeks of taxane-platinum combination chemotherapy and achieved partial or complete response. Patients were assigned to receive 80 mg oral selinexor once weekly or placebo with 2:1 random assignment (ClinicalTrials.gov identifier: NCT03555422). RESULTS Between January 2018 and December 2021, 263 patients were randomly assigned, with 174 allocated to selinexor and 89 to placebo. The medi
Source: ascopubs.orgCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1Molecular mechanism of phosphopeptide neoantigen immunogenicity - Nature Communications - 10 month(s) ago
Phosphorylated peptide antigens are present on cancer cells, but their role in cancer immunity is unknown. Here, the authors describe a molecular mechanism, by which a tumor-specific phosphopeptide found in acute myeloid leukemia is recognized by the human immune T cells.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3What Are the Risk Factors for Uterine Cancer? - 11 month(s) ago
There’s no way to know if you will get uterine cancer, but several factors may increase your chance of getting it.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Let Kids Get Bored. It’s Good for Them. - 11 month(s) ago
A reminder to parents soldiering through the summer: Boredom has its virtues.
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Please wait whilst we redirect you - 11 month(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Yes- so important to include patients of all races/ethnicities in #clinicaltrials! Honored to be leading this effort for GOG-F. Check out our recent manuscript on improving #IDEA in #trials https://t.co/4ZEOLSX16x @GOG @SGO_org @gyncsm @IGCSociety @acog @AACR @ASCO @AACI_Cancer https://t.co/6Oih3BQ0Ud
-
-
Mashup Score: 0SUMMARY - OncLive/State of the Science Summit/Gynecologic Cancers/New York/May 2, 2023 - 1 year(s) ago
OncLive® State of the Science Summit: Disease State, Month Day, Year. Oncology live event features research and clinical advances in oncology.
Source: event.onclive.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Earlier this year, the U.S. House of Representatives approved a spending bill for FY2023 that included significant increases in federal funding for critical ovarian cancer research and education programs. Unfortunately, the U.S. Senate has not yet…
Source: www.votervoice.netCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Categories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0
You must have an ACCC account in order to register for this course. If You DO NOT Have An ACCC Account: To start, click the green “Register” button in the upper right corner of this page. You will be directed to “Your Cart.” Click the green “Log In” button near the top of the page. ACCC members: Click “Reset Password” to update your login information. When your password is updated, you will…
Source: courses.accc-cancer.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1GOG-3052 | ENGOT-ov60 CLINICAL TRIAL REVIEW - 2 year(s) agoSource: YouTubeCategories: Hem/Oncs, Latest HeadlinesTweet
Oral Selinexor as Maintenance Therapy for Endometrial Cancer Journal of Clinical Oncology- impressive benefit noted in pts with p53 #emca. Let’s enroll on Export-EC to confirm! @GOG @SGO_org @IGCSociety @myESMO @ASCO https://t.co/Q1gHaBKclK